2012 MIDO


HEALTH.2013.2.2.1-2: Development of effective imaging tools for diagnosis, monitoring and management of mental disorders. FP7-HEALTH-2013-INNOVATION-1. Two-stage submission procedure. Deadline: 2 October 2012

 

Neuroimaging used as symptomatic Bio-Markers

for the Diagnosis of Psychiatric Disorders

 

 

Name of the coordinating person: Ferran Cabrer i Vilagut. Email: Ferran.Cabrer @ MUFICATA.net

 

List of participants:

No.

Participant organisation name

Country

Type

Person in charge

1

MUFICATA S.L.

ES

SME

Ferran Cabrer

2

Institut Català de la Salut. Hospital Universitari de Bellvitge. Dp. of Psychiatry

ES

HOSP

Carles Soriano-Mas

3

University Medical Center of Amsterdam. Dp. of Psychiatry

NL

HE

Odile Van d. Heuvel

4

Erasmus Medical Center of Rotterdam. Dp. of Psychiatry

NL

HE

Henning Theiner 

5

Ospedale Pediatrico Bambino Gesù (OPBG)

ediatrico Bambino Gesù (OPBG)

IT

 

HOSP

Bruno Bernardi

6

University Hospital Brno. Dp. of Psychiatry

CZ

HOSP

Pavel Tienmer

7

NEUROVOXEL S.L.P.

ES

SME

Jesus Pujol

8

INOVAMAIS S.A.

PT

SME

Joao Correia

9

Masaryk University. Central European Institute of Technologies (CEITEC)

CZ

HE

Tomas Kasparek

10

University of Sheffield. Engineering and Medical Faculties.

UK

HE

A.Frangi/P.Woodruff

11

Foundation for Research and Technology Hellas (FORTH)

GR

RTD

Athanas.Mouchtaris

12

Technical Research Centre of Finland (VTT)

FI

RTD

Kari Antila

13

NISSA TECH S.R.L.

RS

SME

Dragan Vuckovik

14

CROSSLINKS B.V.

NL

SME

Ronald Nanninga

15

BIOTRONICS3D L.T.D.

UK

SME

Harris Hatzakis

16

PARSEK S.R.L.

SV

SME

Janez Bensa

 

Abstract

 

The goal of the proposed MIDO project is to deliver a Mental Imaging Diagnosis Optimiser (MIDO) platform prototype for assisting mental health professionals in the earlier and precise computer-assisted diagnostic of non-degenerative mental disorders, in particular Obsessive-Compulsive Disorders, Schizophrenia, Attention Deficit/Hyperactivity Disorder and their early detection in children, progression monitoring and patient' population stratification.

This will be achieved by the collection and analysis of existing Neuro-Images (NIMG), the identification of relevant symptomatic biomarkers (BMK) and the extraction of the graphical, mathematical and clinical models that represent a significant symptom across a sizeable patient' population. Subsequent work will include their optimisation, validation, semantic “profiling” classification and publication for use locally as “models of reference”.

These normative BMK will be obtained from two main different NIMG types: (i) High Definition three-Dimensional Definition Anatomical neuroimaging and (ii) Echo Planar neuroimaging of BOLD signal at rest.

The consortium of top-level European hospitals, NIMG research departments and industrial partners will build up collectively the taxonomy, the network databases and the application's repositories for updating and upgrading regularly the systems for psychiatrists and neuropsychiatrists which will increase progressively their diagnosis accuracy, efficiency, usability and serviceability for the diagnostic of OCD, SCZ and ADHD and in the future for other MD such as: Anxiety, Panic, Depression, Phobia and Stress.

MIDO will assist clinicians in the NIMG analysis and MD diagnosis by providing collaborative spaces and development tools, facilities, training contents, useful libraries of validated new BMK for visual comparison, computer's diagnostics and automatic advice.

MIDO will be designed and developed in collaboration with multidisciplinary specialists and deployed in real-world hospital/clinical scenarios to validate platform features and evaluate performance. The novel cloud paradigm of the platform will facilitate improved multi-disciplinary and consortium collaboration and cohesion, and smaller iteration cycles.

 

At the end of the three-year MIDO project, the delivered novel distributed database and facilities for NIMG research and analysis and clinical diagnostic of MD will create standard protocols, collaborative environments and a service market, assuring sustainable development, adoption throughout Europe and European leadership.